scout

Authors

Sponsored Q&A by Dr. Wang
Dr. Robert Dreicer
Jane Delartigue, PhD
Latest Article

Tumor Agnostic Role of TMB Biomarker Faces Challenges

Although tumor mutational burden is established as a clinically informative feature of tumors, its optimal use in therapeutic decision-making faces many challenges, and we are only beginning to fully understand its strengths and limitations.

Abramson Cancer Center
Latest Article

Julia “Julie” Borrelli Named Chair of the Abramson Cancer Center Director's Leadership Council

Julia “Julie” Borrelli has been appointed chair of the Abramson Cancer Center Director's Leadership Council.

Paul V. Viscuse, MD
Latest Article

Applying ASCO GU 2024 Data to Clinical Practice in Bladder, RCC Care

Paul V. Viscuse, MD, spotlights key data from the 2024 Genitourinary Cancers Symposium in bladder cancer and renal cell carcinoma.

Jacob N. Stein, MD, MPH
Latest Article

From Anguish to Action: Turning Despair Into Efforts to Improve Racial Equity

Oncology fellows at the University of North Carolina turned their despair over the murders of George Floyd and Breonna Taylor into an effort to improve racial equity.

Timothy J. Brown, MD
Latest Article

Finding the Optimal Therapeutic Sequence for Advanced Hepatocellular Carcinoma

Several breakthroughs in recent years have rapidly shifted the treatment landscape for advanced HCC.

Tracy Ann Politowicz
Latest Article

Efforts to Leverage NaPi2b Are Renewed With Novel ADC in Ovarian Cancer

Initial activity and safety with the investigational ADC TUB-040 in ovarian cancer have renewed interest in NaPi2b as a target for ADC development.

American Oncology Network
Latest Article

American Oncology Network Celebrates Momentous Five-Year Anniversary of Closing the Cancer Care Gap

American Oncology Network, one of the fastest-growing community oncology networks in the United States, proudly celebrated its fifth anniversary, commemorating a half-decade of excellence in advancing community oncology and driving value-based care initiatives to close the cancer care gap.

Krystal L. Cleven, MD, MS
Latest Article

The Importance of Lung Cancer Screening in Individuals Exposed to the World Trade Center Disaster

Investigators evaluated risk factor–based guidelines and risk model–based strategies for lung cancer screening in World Trade Center–exposed responders.

UCSF Health
Latest Article

Uncovering Why Cancer Immunotherapy Leads to Heart Inflammation

A study led by UC San Francisco researchers found that anti-LAG-3/anti-PD-1 combination therapy shows a higher risk of myocarditis vs other ICI treatments.

Kelly King
Latest Article

NALIRIFOX Remains Effective Despite Dose Modification in First-Line PDAC

In an OncLive Peer Exchange, experts convened to discuss notable updates in pancreatic cancer from ASCO GI and beyond.

Quan T. Dang, MD
Latest Article

Palliative Care Can Address Gaps in Oncology Landscape

Palliative medicine has evolved to become a standard for high-quality cancer care, helping patients relieve suffering throughout their journey, improving quality of life, and prolonging survivorship.

Julie E. Chang, MD
Latest Article

COVID-19 Pandemic Highlights Underrecognized Vulnerability of Patients With CLL

At the onset of the pandemic, hematology/oncology physicians were challenged in counseling patients with serious underlying malignant conditions about their risk for severe disease due to COVID-19.

Fox Chase Cancer Center
Latest Article

Study Finds Radiation Therapy Administered Before Surgery Rarely Shrinks Retroperitoneal Sarcoma Tumors

Radiation therapy administered prior to surgery rarely shrinks retroperitoneal tumors in sarcoma according to Fox Chase Cancer Center researchers.

Roger Y. Kim, MD, MSCE
Latest Article

Immune Checkpoint Inhibitors Extend Survival for Mesothelioma

Immune checkpoint inhibitor therapies have ushered in an exciting new phase of clinical research and treatment for malignant pleural mesothelioma.

Gwendolyn M. Bryant-Smith, MD
Latest Article

Comprehensive Treatment Advances Care for Patients With Early-Stage Breast Cancer

Advances in the diagnosis and treatment of early-stage breast cancer highlight the need for clinicians to adapt to paradigm shifts that will have notable effects on patient care.

Joern-Peter Halle, Global Head of Research at Merck KGaA, Darmstadt, Germany*
Joern-Peter Halle, Global Head of Research at Merck KGaA, Darmstadt, Germany*
Latest Article

Discovering New Medicines in Cancer

Our ambition is to outsmart cancer by translating our science into health. The combination of our people and heritage is a particular advantage we have in achieving this goal. Our teams are curious, bold, and driven to deliver potentially transformative medicines to patients with cancer. Our heritage of science-based precision medicine and immuno-oncology means that we can branch into synergies to bridge different aspects of cancer research, in an agile and uncompromising manner. Our research focus is on three key mechanistic pillars: oncogenic pathways; immuno-oncology (IO); and DNA damage response (DDR); and, we are developing new approaches in key tumor types in GI, GU and thoracic cancers, all areas with significant unmet treatment needs. Together, we are transforming cancer care—today and tomorrow.

Alex Biese
Latest Article

Mobile Health Intervention Improves QOL in AYA Breast Cancer Survivors

A mobile health intervention was associated with improvements to general and cancer-specific quality of life in AYA breast cancer survivors.

Benjamin Saylor
Latest Article

Gemcitabine Intravesical System Yields Low Rate of Radical Cystectomy in BCG-Unresponsive, High-Risk NMIBC

Gemcitabine intravesical system in BCG-unresponsive, high-risk NMIBC led to high CR rates and low radical cystectomy rates.

Panagiotis J. Vlachostergios, MD, PhD
Latest Article

Antibody-Drug Conjugates Carve Out Space in Urothelial Carcinoma Landscape

Monoclonal antibodies have played a key role in the development of personalized oncology and have proven antitumor activity through multiple mechanisms, including direct transmembrane signaling leading to apoptosis, complement mediated cytotoxicity, antibody-dependent cellular cytotoxicity, and inhibiting tumor vasculature and stroma.

Michelle Chi, MD
Latest Article

Assessing Bleeding Disorders: Keys for Hem/Onc Fellows

Michelle Chi, MD and Jennifer R. Green, MD, share practical points for trainees to approach the initial evaluation for a bleeding-disorder patient.

Dr. Mitesh Borad
Rylan DeStefano
Latest Article

Acimtamig Plus Allogeneic Natural Killer Cells Under Phase 2 Evaluation in R/R Hodgkin Lymphoma and CD30+ PTCL

Following promising preclincial findings, acimtamig plus allogenic natural killer cells will be examined for the treatment of patients with relapsed/refractory Hodgkin lymphoma and CD30-positive peripheral T-cell lymphoma.

David Schiff, MD
Latest Article

Dr Schiff on PFS and OS Data With Temozolomide Plus Radiation in Grade II Glioma

David Schiff, MD, discusses PFS and OS data for radiation with or without temozolomide in patients with grade II glioma.

Shiruyeh Schokrpur, MD, PHD
Latest Article

PD-L1 Status Stratifies Immunotherapy Treatment in NSCLC

Data from completed studies evaluating immunotherapy in lung cancer alone or in combination with chemotherapy show that a breakdown of populations by PD-L1 status and additional considerations such as toxicity profiles should guide treatment decisions.

Santosh L. Saraf, MD
Latest Article

Education Is a Personal Mission

Santosh Saraf, MD, changed his major 3 times as an undergrad at Penn State University, bouncing from premed to mathematics to marine biology before settling back into medicine.

Gerhard Hildebrandt, MD, FACP
Latest Article

Reflecting on Research Highlights in Acute Leukemia and Multiple Myeloma With Drs Hildebrandt and Baljevic

Gerhard Hildebrandt, MD, FACP, and Muhamed Baljevic, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in acute leukemia and multiple myeloma presented during the 2025 ASH Annual Meeting & Exposition.

Justine Yang Bruce, MD
Justine Yang Bruce, MD

Justine Yang Bruce, MD, is a faculty member in the Division of Hematology, Medical Oncology and Palliative Care within the Department of Medicine at the University of Wisconsin, as well as the director of the VA Medical Oncology Clinical Research Program and dhair of the Protocol Review and Monitoring Committee at the University of Wisconsin Carbone Cancer Center

Latest Article

Toripalimab Plus De-Intensified Chemo Represents the Potential Future of Nasopharyngeal Cancer Management: With Justine Bruce, MD

Dr Bruce discusses treatment strategies for nasopharyngeal cancer, including how first-line toripalimab plus chemotherapy has shown improved OS.

Gustavo Rivero, MD, is the director of translational research for myeloid disorders at Tampa General Hospital Cancer Institute in Florida and an associate professor of hematology/oncology.
Gustavo Rivero, MD

Gustavo Rivero, MD, is the director of translational research for myeloid disorders at Tampa General Hospital Cancer Institute in Florida and an associate professor of hematology/oncology.

Latest Article

Targeting Menin: A New Frontier in Treating Refractory Leukemias

Incorporation of menin inhibitors is central to improving the outcome of difficult-to-treat leukemias.